Paula R. Clemens
Affiliations: | University of Pittsburgh, Pittsburgh, PA, United States |
Area:
Genetics, Neuroscience Biology, ImmunologyGoogle:
"Paula Clemens"Mean distance: 21373.2
Children
Sign in to add trainee| Soyoung C. Gilchrist | grad student | 2002 | University of Pittsburgh |
| Laura R. Goldberg | grad student | 2003 | University of Pittsburgh |
| Bhanu M. Koppanati | grad student | 2009 | University of Pittsburgh |
| Saman Eghtesad | grad student | 2010 | University of Pittsburgh |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Clemens PR, Gordish-Dressman H, Niizawa G, et al. (2023) Findings from the Longitudinal CINRG Becker Natural History Study. Journal of Neuromuscular Diseases |
| Reay DP, Tabib T, Wang Y, et al. (2023) Antigen-driven T cell-macrophage interactions mediate the interface between innate and adaptive immunity in histidyl-tRNA synthetase-induced myositis. Frontiers in Immunology. 14: 1238221 |
| Madrid DA, Knapp RA, Lynch D, et al. (2023) Associations between Lower Extremity Muscle Fat Fraction and Motor Performance in Myotonic Dystrophy Type 2: A Pilot Study. Muscle & Nerve |
| Dang UJ, Ziemba M, Clemens PR, et al. (2020) Serum biomarkers associated with baseline clinical severity in young steroid-naive Duchenne muscular dystrophy boys. Human Molecular Genetics |
| Clemens PR, Niizawa G, Feng J, et al. (2020) The CINRG Becker Natural History Study: Baseline Characteristics. Muscle & Nerve |
| Clemens PR, Rao VK, Connolly AM, et al. (2020) Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial. Jama Neurology |
| Hoffman EP, Schwartz BD, Mengle-Gaw LJ, et al. (2019) Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology |
| Hathout Y, Liang C, Ogundele M, et al. (2019) Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy. Scientific Reports. 9: 12167 |
| Kishnani P, Schoser B, Bratkovic D, et al. (2019) First-in-human study of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in patients with Pompe disease: preliminary functional assessment results from the ATB200-02 trial Molecular Genetics and Metabolism. 126: S86 |
| Clemens P, Mengle-Gaw L, Smith E, et al. (2019) P.338Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function Neuromuscular Disorders. 29 |